Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

An international randomised trial of radical surgery followed by adjuvant therapy versus no further treatment in patients with early-stage, … Recruiting

2023-504973-19-01 early-stage, intermediate-risk cervical cancer 5 2023-09-06
MARSUN: Evaluation of the benefits of the combination of Mosunetuzumab-Lenalidomide versus a treatment chosen by the investigator in Patient… Recruiting

2022-501810-77-00 Relapsed or Refractory Marginal Zone Lymphoma 5 2023-09-01
Neo-adjuvant Chemo and immunotherapy with durvalumab (MEDI4736) and tremelimumab (MEDI1123) In The pre-operAtive Treatment of locally advanc… Recruiting

2024-518656-23-00 locally advanced cholangiocarcinoma 4 2023-09-01
Tebentafusp Regimen Versus Investigator’s Choice in Previously Treated Advanced Melanoma (TEBE-AM) Recruiting

2022-502732-39-00 Previously treated non-ocular advanced melanoma 10 2023-09-01
A Phase 1 study of LOXO-435 in Locally Advanced or Metastatic Solid Tumors with FGFR3 Gene Alterations Recruiting

2022-502755-59-00 Locally Advanced or Metastatic Solid Tumors with FGFR3 1 2023-08-30
Effect of low-dose Interferon-alfa2a on perioperative immune suppression Recruiting

2024-517619-65-00 Colon cancer 4 2023-08-28
Does peri-operative treatment with Tranexamic Acid reduce the early relapse rate for patients with melanoma; a randomised controlled trial Recruiting

2022-502633-26-00 Melanoma Surgery 5 2023-08-25
An open-label, multicentre, rollover study to evaluate safety and antineoplastic activity of OATD-02 in patients with selected advances and/… Recruiting

2024-513006-61-00 Advanced and/or metastatic solid tumours (colorectal ca 3 2023-08-23
A Phase 1, Open-Label, Dose-Escalation Study to Determine an Appropriate Starting Dose of Sacituzumab Govitecan in Subjects With Advanced or… Recruiting

2022-501508-82-00 Solid Tumors 3 2023-08-23
The iCaD Study Recruiting

2022-503026-12-00 Immune checkpoint inhibitor related colitis 5 2023-08-22
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination with Checkpoint Inhibitor i… Recruiting

2023-504709-35-00 Locally advanced or metastatic solid tumors 1 2023-08-16
A Prospective Phase I/II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Tafasitamab (MOR00208) in Pediatr… Recruiting

2024-511336-28-00 Leukemia in childhood 9 2023-08-11
A Phase I/II First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Anti-Tumor Activity of IMA402, a Bispecific T Cell-Engag… Recruiting

2022-503133-54-00 Solid Tumors 7 2023-08-09
First-in-human, Phase 1/2, open-label, multicenter, dose-escalation and expansion study Recruiting

2022-502645-99-00 MTAP-deleted Advanced or Metastatic Solid Tumors 7 2023-08-09
A study to evaluate the safety and efficacy of the tumor-targeting human antibody-cytokine fusion protein L19TNF plus lomustine in patients … Recruiting

2022-501822-39-00 Glioblastoma 9 2023-07-31
CHIP-AML22 Master protocol: Protocol for the treatment of children and adolescents with Acute Myeloid Leukemia (AML) Recruiting

2023-504999-25-00 Acute Myeloid Leukemia 5 2023-07-14
Phase I/II study with galunisertib combined with capecitabine in patients with advanced chemotherapy resistant colorectal cancer with perito… Recruiting

2024-518980-37-00 colorectal cancer 9 2023-07-12
A Study of Subcutaneous Nivolumab + Relatlimab FDC in Previously Untreated Metastatic or Unresectable Melanoma (RELATIVITY-127) Recruiting

2022-500967-11-00 Previously Untreated Metastatic or Unresectable Melanom 5 2023-07-06
A Phase 1 Safety and Dose Finding Study of 131I -TLX101 Plus Standard of Care in Patients with Newly Diagnosed Glioblastoma Recruiting

2024-515466-13-00 Glioblastoma multiforme (GBM) 3 2023-06-28
Continuing Somatostatin Analogues Upon progression in Neuroendocrine tumour pAtients (SAUNA trial) Recruiting

2022-502703-30-00 neuroendocrine tumours 6 2023-06-28
A phase II randomized trial of Lu-PSMA and Stereotactic Radiotherapy versus Radiotherapy alone for oligometastatic prostate cancer (LUST) Recruiting

2024-519347-15-00 Oligometastatic prostate carcinoma 4 2023-06-27
Oxaliplatin ± nivolumab in combination with trifluridine/tipiracil or 5- fluorouracile ± nivolumab in frail patients with advanced, recurren… Recruiting

2024-512999-35-00 Patients with HER 2 negative locally advanced, recurren 4 2023-06-23
A Randomized Trial of Trastuzumab Deruxtecan and Biology-Driven Selection of Neoadjuvant Treatment for HER2-positive Breast Cancer Recruiting

2022-501504-95-00 Non-metastatic HER2-positive Breast Cancer 4 2023-06-23
Genomics guided targeted post-neoadjuvant therapy in patients with early breast cancer – a multicenter, open-label, umbrella phase-II study … Recruiting

2024-514022-23-00 Early breast cancer 4 2023-06-23